Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients

Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, Luca Corradi, Paola Preti, Pierangelo Lazzari, Giuseppe Derosa

Research output: Contribution to journalArticle

Abstract

Background: This study compared the effects of losartan and perindopril on plasma plasminogen activator inhibitor-1 (PAI-1) and fibrinogen in hypertensive type 2 diabetic patients. Methods: We studied 85 nonsmoking outpatients, aged 46 to 64 years, with mild to moderate essential hypertension (diastolic blood pressure [BP] >90 and 1 receptor blockade and could rather be due to the fact that the endothelial receptors that mediate PAI-1 expression in response to angiotensin II are not type 1 receptor subtypes. Different effects of the two drugs on the bradykinin system might also be implicated.

Original languageEnglish
Pages (from-to)316-320
Number of pages5
JournalAmerican Journal of Hypertension
Volume15
Issue number4 I
DOIs
Publication statusPublished - 2002

Keywords

  • Diabetes
  • Fibrinogen
  • Hypertension
  • Losartan
  • PAI-1 antigen
  • Perindopril

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients'. Together they form a unique fingerprint.

  • Cite this